VWM
TBPH icon

Venturi Wealth Management’s Theravance Biopharma TBPH Stock Holding History

Venturi Wealth Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-526
Closed -$4.95K – 1682
2024
Q4 		$4.95K Buy
+526
New +$4.79K ﹤0.01% 1673

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Venturi Wealth Management's TBPH Position: Q1 2025 in Review

Venturi Wealth Management sold out of Theravance Biopharma (TBPH) in Q1 2025, closing a stake of 526 shares — an estimated $4.95K sold.

Venturi Wealth Management first reported a position in TBPH in Q4 2024 and held it in 1 quarter. The position peaked at $4.95K in Q4 2024. 131 funds tracked by Wall St. Rank hold TBPH as of Q1 2025.

  • Venturi Wealth Management reported no remaining Theravance Biopharma position as of Q1 2025 after selling out during the quarter.
  • Venturi Wealth Management sold 526 Theravance Biopharma shares in Q1 2025, an estimated $4.95K.
  • Venturi Wealth Management first reported a position in Theravance Biopharma in Q4 2024 and held it in 1 quarter.
  • Venturi Wealth Management's Theravance Biopharma position peaked at $4.95K in Q4 2024.
  • 131 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2025.

Based on Venturi Wealth Management's 13F filing for Q1 2025, filed 6 May 2025.